Compare iShares MSCI France ETF (EWQ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI France ETF trades at $41.43 (market cap $330.91M), while Neurocrine Biosciences Inc trades at $141.5 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 43.4× iShares MSCI France ETF's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 55 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EWQ | NBIX | |
|---|---|---|
Market Cap | $330.91M | $14.36B |
Volume | 556,654 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $185.50 |
52-Week Low | $41.32 | $123.10 |
Typical Hold Time | 55 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is currently trading at $41.34, down 1.12% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock faces significant technical pressure with moving averages signaling strong selling momentum. Recent news highlights European market volatility driven by ECB rate hikes and energy price inflation, creating headwinds for European-focused investments.
The outlook remains cautious as monetary tightening and geopolitical risks weigh on European equities. Key support sits at $41 with resistance at $42, while oversold conditions suggest potential for near-term stabilization. However, sustained recovery depends on easing inflation pressures and improved eurozone economic sentiment.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
